U.S. STERILE INJECTABLES MARKET ANALYSIS

Injectables are preparations administered through the skin or other external boundary tissue, rather than through the alimentary canal, so that the active substance they contain are administered, using gravity or force, directly into a blood vessel, organ, tissue, or lesion. The injectable preparation are administered through subcutaneous, intravenous, and intramuscular route of administration.

The containers, including the closures, for preparation for injectables do not interact physically or chemically with the preparations in any manner to alter the strength, quality, or purity beyond the official requirements.

The U.S sterile injectables market is estimated to be valued at US$ 131.8 billion in 2022 and expected to exhibit a CAGR of 9.3% over the forecast period (2022-2030).

Figure 1. U.S Sterile Injectables Market Share (%), by Molecule Type, 2022

To learn more about this report, request a free sample copy

Increasing prevalence of type 1 and type 2 diabetes and cancers is expected to drive the growth of the U.S sterile injectables market over the forecast period.

For instance, according to American Diabetes Association, in 2018, 34.2 million Americans or 10.15% of the population, had diabetes. Moreover, nearly 1.6 million Americans have type 1 diabetes, including about 187,000 children and adolescents.

Increasing research and development activities for the treatment of chronic diseases such as HIV is expected to drive the market over the forecast period.

For instance, in January 2022, Moderna, Inc. American pharmaceutical and biotechnology company based in Cambridge Massachusetts that focuses on RNA technology has started clinical trial for HIV vaccine, the first vaccination was given at George Washington University School of Medicine and Health Sciences in Washington DC.

Increasing product launches and approval is expected to drive the market growth over the forecast period.

For instance, in July 2021, AstraZeneca’s BYDUREON BCise (exenatide extended release), once weekly injectable suspension has been approved in the U.S for the treatment of type 2 diabetes (T2D) to improve glycemic control in pediatric patients (10 to 17 years) as an adjunct to diet and exercise. 

Figure 2. U.S Sterile Injectables Market Share (%), by Distribution Channel, 2022

To learn more about this report, request a free sample copy

U.S Sterile Injectables Market – Impact of Coronavirus (COVID-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 63,397,935 cases due to coronavirus (COVID-19) were reported till January 12, 2022, in the U.S.

COVID-19 has had a positive impact on the sterile injectables market as lot of people got infected with COVID-19 infection and severely infected people have to get admitted to the hospitals, while on the other hand most of the U.S population have got vaccinated to stop the spread of virus.

For instance, the U.S vaccination program began on December 14, 2020. As of January 27, 2022, 536.4 million vaccine doses have been administered in the U.S. Overall, about 249.3 million people or 75.1% of the total U.S population, have received at least one dose of vaccine.

U.S Sterile Injectables Market - Restraint

Factors restraining the U.S sterile injectables market growth include product recall due to sterility failure in injectables. For instance, in January 2022, AuroMedics Pharma LLC, is located in east Windsor, NJ, U.S, issued voluntary nationwide recall of Polymyxin B for injection USP, 500,000 unit per vial, due to the presence of particular matter. 

Key Players

Major players operating in the U.S sterile injectables market include Baxter International Inc., AstraZeneca plc, Merck & Co., Inc., Novartis AG, Johnson & Johnson Services, Inc., Gilead Sciences, Inc., JHP Pharmaceuticals, Pfizer Inc., Fresenius Kabi Ag, CordenPharma, and Hikma Pharmaceuticals PLC.